Archives: Premium Distribution

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) will develop the 6.9 MW DC Brooklyn solar project in Nova Scotia under Canada’s first Community Solar Program. Owned by AI Renewable Fund, the $13.9 million project will be built in partnership with local firm Trimac Engineering. The program supports Nova Scotia’s goal of reaching 80% renewable energy by 2030 and net-zero by 2035. SolarBank will oversee interconnection, permitting, and design through 2025, with construction expected to begin in spring 2026. The company also disclosed a shares-for-services agreement with an independent advisor valued at up to $100,000 USD per month, tied to strategic growth and advisory milestones. 

To view the full press release, visit https://ibn.fm/dAmjf 

About SolarBank Corporation 

SolarBank Corporation is an independent renewable and clean energy project developer and owner focusing on distributed and community solar projects in Canada and the USA. The Company develops solar, Battery Energy Storage System (BESS) and EV Charging projects that sell electricity to utilities, commercial, industrial, municipal and residential off-takers. The Company maximizes returns via a diverse portfolio of projects across multiple leading North America markets including projects with utilities, host off-takers, community solar, and virtual net metering projects. The Company has a potential development pipeline of over one gigawatt and has developed renewable and clean energy projects with a combined capacity of over 100 megawatts built.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

• Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network of psychiatric clinics.
• The acquisition brings profitability and is expected to be accretive to both revenue and EBITDA.
• Kadima’s founder and medical director, Dr. David Feifel, a leader in interventional psychiatry, will join HOPE as Chief Medical Innovation Officer.
• NRx’s pipeline includes investigational drugs for suicidal bipolar depression and chronic pain.
• HOPE is targeting 30 clinic acquisitions by the end of 2025, projecting $100M in annual revenue.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly owned subsidiary HOPE Therapeutics, Inc., a medical and technology-driven company, are expanding their footprint in the mental health care sector with the acquisition of Kadima Neuropsychiatry Institute in La Jolla, California. The companies announced the signing of a definitive agreement to purchase the institute earlier in May 2025. Kadima is expected to serve as the clinical template for HOPE’s planned network of interventional psychiatry clinics across the U.S. (https://ibn.fm/uwHMj).

One of California’s flagship interventional psychiatry clinics, Kadima is recognized for integrating clinical care with research into emerging treatments such as psychedelic medications, and transcranial magnetic stimulation (“TMS”). The clinic offers a full range of treatments for suicidal depression, PTSD and other…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

• Intelligent Bio Solutions remains on track for a 2025 U.S. launch of its non-invasive Intelligent Fingerprinting Drug Screening System.
• The company’s FDA 510(k) submission included validation studies showing 94.1% accuracy in detecting opiates through fingerprint sweat.
• INBS is already active in 24 countries, with over 450 commercial accounts globally, and adoption growing across diverse industries, including logistics, mining, retail, and marine operations.
• The firm is expanding its distributor network to support localized growth ahead of its U.S. market entry.

Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, is preparing for its expected U.S. launch in 2025, as it is progressing through the FDA clearance process for its Intelligent Fingerprinting Drug Screening System. The non-invasive device, which detects recent drug use via fingerprint sweat, is gaining international traction for its speed, portability, and ability to integrate into a range of safety-critical environments.

On Dec. 18, 2024, INBS submitted a 510(k) premarket notification to the U.S. Food and Drug Administration, seeking clearance for its opiate test system for codeine (https://ibn.fm/YVRNE). The FDA classified the system as a Class II medical device, which requires this form of submission. As of March…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to INBS are available in the company’s newsroom at https://ibn.fm/INBS

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is leading the way with innovative therapies for rare and difficult-to-treat diseases, particularly early-stage cutaneous T-cell lymphoma (“CTCL”), a rare form of cancer that affects the skin. “Soligenix’s proprietary treatment, HyBryte(TM), is currently in clinical trials, and the latest results have shown promising efficacy in treating CTCL,” reads a recent article. “‘Following 18 weeks of treatment, 75% of patients achieved ‘Treatment Success,’ reinforcing HyBryte(TM) as a potentially safe and fast-acting therapy for this chronic and underserved cancer,’ the company reported. The study results suggest that the treatment may be highly effective in reducing the symptoms of CTCL, providing much-needed hope for patients with this challenging condition.”

To view the full article, visit https://ibn.fm/YTuos

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.

The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).

For further information, visit the company’s website at www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

• AVERSA Fentanyl has potential to become the world’s first opioid pain patch with abuse deterrent properties, CEO states in report
• Nutriband and Kindeva Drug Delivery have formalized a strong product-development partnership and long-term commitment
• Other key steps outlined as company works to develop, scale-up manufacturing process to bring Aversa technology closer toward commercialization

In a recent report to shareholders, Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan shared significant company achievements and milestones as well as his expectations for 2025 (https://ibn.fm/9K5zT). At the center of the company’s positive outlook for future is noteworthy progress made toward the commercialization of its proprietary Aversa technology, including a strong partnership with Kindeva Drug Delivery.

“Nutriband is primarily focused on working with our partner Kindeva Drug Delivery, a leading global contract development and manufacturing organization focused on drug-device combination products, to develop our lead product, AVERSA(TM) Fentanyl, which incorporates Nutriband’s…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Newton Golf Company (NASDAQ: NWTG) is revolutionizing golf performance through its high-quality, custom-fitted shafts engineered to match individual swing dynamics. Recognizing the shaft as the “engine” of the club, Newton leverages advanced technology to optimize swing speed, ball trajectory and overall control. Crafted in the U.S. and engineered to meet the demands of players on professional tours, 30 PGA TOUR Champions players trust the shaft—including major winner Doug Barron. From seasoned pros to players across all skill levels, the company delivers precision equipment that minimizes inconsistencies and enhances shot accuracy for all golf enthusiasts. As personalized equipment gains traction in the golf industry, Newton Golf is emerging as a leader, helping players unlock their true potential on the course.

To view the full article, visit https://ibn.fm/g7yAn

About Newton Golf Company Inc.

Newton Golf harnesses the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, the company’s rebranding reflects its commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of its design process, Newton Golf creates precision-engineered golf clubs that deliver unmatched stability, control, and performance. The company’s mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics.

For more information, visit the company’s website at www.NewtonGolfIR.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Intelligent Bio Solutions (NASDAQ: INBS) announced its participation at the RISE25 conference in Kissimmee, Florida, from May 28 to 31, 2025, where it will support U.S. distribution partner SMARTOX. INBS will demonstrate its Intelligent Fingerprinting Drug Screening System—a non-invasive, rapid test using fingerprint sweat to detect substances like THC, cocaine, methamphetamine, and opiates. With results delivered in under 10 minutes, the technology is well-suited for treatment courts and justice applications. INBS views the event as a key platform to engage stakeholders as it advances toward U.S. market entry. 

To view the full press release, visit https://ibn.fm/r2No2 

About Intelligent Bio Solutions Inc. 

Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. 

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to INBS are available in the company’s newsroom at https://ibn.fm/INBS

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Brera Holdings (NASDAQ: BREA) announced that S.S. Juve Stabia’s Serie B semifinal playoff match against Cremonese will stream live and air free today in the U.S., Canada and UK via Destination Calcio TV, with full English commentary. The broadcast reflects Brera’s commitment to internationalizing its portfolio club’s exposure as part of its multi-club ownership strategy. Executive Chairman Daniel McClory emphasized that expanding Juve Stabia’s global visibility during its Serie A playoff run showcases the company’s focus on fanbase growth and international media rights. The club, which finished 5th in Serie B, advanced to the semifinals after defeating Palermo 1-0.

To view the full press release, visit https://ibn.fm/R1pGT

About Brera Holdings PLC

Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.

For more information, visit the company’s website at www.BreraHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at http://ibn.fm/BREA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that Founder and CEO Dr. Jonathan Javitt will deliver a company update at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida. NRx is one of six companies invited to present at the high-profile event, which is expected to draw more than 1,000 attendees representing over $1 trillion in investment capital.

The presentation will highlight the company’s progress toward FDA approval of NRX-100, a preservative-free intravenous ketamine formulation, as well as its strategic acquisition plans for HOPE clinics focused on treating suicidal depression, PTSD, and related conditions.

To view the full press release, visit https://ibn.fm/eYj6T

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

For more information, please visit https://www.nrxpharma.com/

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Disseminated on behalf of SolarBank Corporation

• CEO Dr. Richard Lu discussed SolarBank’s vertically integrated business model on a recent GotStocks podcast.
• SolarBank is an expanding developer, builder, operator, and owner of clean energy projects across North America, maintaining a $184 million portfolio of assets generating recurring revenue.
• The company’s flexible supply chain strategy helps mitigate any tariff risks while reducing costs.
• Going forward, a recently announced up to $100 million transaction with CIM Group is set to fund up to 97 MW of U.S. community solar projects.

Dr. Richard Lu, CEO of SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., offered insights into the company’s operations, strategy, and unique competitive position during a recent interview on IBN’s GotStocks podcast (https://ibn.fm/UCIdQ). The conversation centered on SolarBank’s dual role as both a developer and long-term owner of solar energy assets, an approach that differentiates the firm in a competitive market.

“SolarBank is both a developer and an independent power producer,” Lu said. The company identifies suitable sites, secures permits, engages utilities, and finances projects. “As a developer, we secure sites for clean and renewable energy project development. We bring the projects to the attention of local…

Read More>>

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

• Siyata Mobile is gaining traction across North America with its purpose-built push-to-talk (PTT) devices and Uniden(R)-branded cellular signal boosters.
• Its SD7 handset offers a rugged, LTE-based replacement for traditional two-way radios in public safety and industrial sectors.
• Signal boosters enhance connectivity in vehicles, buildings, and remote zones, supporting mission-critical communications.
• Distribution wins with major U.S. carriers and public sector agencies highlight growing demand and deployment momentum.
• The company’s carrier-integrated model aligns with rising needs for scalable, reliable communication infrastructure.

Siyata Mobile Inc. (NASDAQ: SYTA) is a technology company providing advanced communication solutions for frontline workers, emergency responders, and mobile workforces. Its core offerings include the SD7 push-to-talk handset and Uniden(R)-branded signal boosters, both designed to improve operational connectivity where traditional networks fall short. These products are FCC- and IC-certified and distributed through Tier-1 carriers, integrators, and government purchasing channels.

The company’s integrated model supports wide-scale deployments across North America, offering a cost-effective alternative to legacy land mobile radios. Siyata is actively expanding in sectors such as…

Read More>>

For more information, visit the company’s website at https://ir.siyata.net.

NOTE TO INVESTORS: The latest news and updates relating to SYTA are available in the company’s newsroom at http://ibn.fm/SYTA

About AINewsWire

AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.

AINW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit www.AINewsWire.com

Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer

AINewsWire
Los Angeles, CA
www.AINewsWire.com
310.299.1717 Office
[email protected]

AINewsWire is powered by IBN

Mullen Automotive (NASDAQ: MULN) reported $5 million in revenue for the quarter ended March 31, 2025, a significant increase from $33,000 in the prior-year period, driven by deliveries of Class 1 and Class 3 electric vehicles to customers including logistics firms, local governments and universities. The company also highlighted new agreements, such as a supply deal with Enpower Greentech for advanced solid-state batteries and expanded public sector eligibility via Sourcewell contracts. Bollinger Motors, a majority-owned subsidiary, delivered Class 4 trucks but was placed into court-appointed receivership in May, a move Mullen says will not materially impact its liquidity. For the six-month period, Mullen recorded $7.9 million in revenue and a net loss of $162 million, with $118 million tied to non-cash expenses. Cash on hand declined to $2.3 million, and the company is continuing cost-reduction efforts and financing through convertible securities. 

To view the full press release, visit https://ibn.fm/kS3g8 

About Mullen Automotive Inc. 

Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com. 

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About GreenEnergyStocks

GreenEnergyStocks (“GES”) is a specialized communications platform with a focus on companies working to shape the future of the green economy. GreenEnergyStocks is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled recognition and brand awareness. GES is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from GreenEnergyStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenEnergyStocks.com

Please see full terms of use and disclaimers on the GreenEnergyStocks website applicable to all content provided by GES, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer

GreenEnergyStocks
Austin, Texas
www.GreenEnergyStocks.com
512.354.7000 Office
[email protected]

GreenEnergyStocks is powered by IBN

NextPlat (NASDAQ: NXPL, NXPLW) announced that its subsidiary, Global Telesat Communications Ltd (GTC), has been appointed the exclusive distributor for ZOLEO Inc. across the UK and European Economic Area. ZOLEO’s flagship global satellite communicator extends smartphone messaging coverage via the Iridium(R) satellite network and has earned accolades including Outdoor Retailer’s Innovation Award “Product of the Year.” The partnership adds to GTC’s expanding e-commerce and Amazon storefront portfolio of satellite connectivity solutions for remote workers, outdoor enthusiasts, and global travelers.

To view the full press release, visit: https://ibn.fm/SLpPL

About NextPlat Corp

NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care Inc.

NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Austin, Texas
www.TechMediaWire.com
512.354.7000 Office
[email protected]

TechMediaWire is powered by IBN

Thumzup (NASDAQ: TZUP) announced that CEO Robert Steele will present at the 82nd Emerging Growth Conference on May 21, 2025, at 11:25 a.m. ET. The company will showcase its disruptive platform that pays everyday consumers to post about participating brands on social media, enabling scalable, user-generated advertising. Hosted virtually, the conference highlights innovative small- and micro-cap companies positioned for long-term growth.

To view the full press release, visit https://ibn.fm/cKkso

About Thumzup(R)

Thumzup Media Corporation is democratizing the multi-billion dollar social media branding and marketing industry. Its flagship product, the Thumzup platform, utilizes a robust programmatic advertiser dashboard coupled with a consumer-facing App to enable individuals to get paid cash for posting about participating advertisers on major social media outlets through the Thumzup App. The easy-to-use dashboard allows advertisers to programmatically customize their campaigns. Cash payments are made to App users/creators through PayPal and other digital payment systems.

Thumzup was featured on CBS Los Angeles and in KTLA.

NOTE TO INVESTORS: The latest news and updates relating to TZUP are available in the company’s newsroom at https://ibn.fm/TZUP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

• Q1 milestones are representative of Soligenix’s commitment to advance its pipeline of therapeutic candidates, focusing on areas with significant unmet medical needs.
• The company noted positive interim results from the ongoing open-label, investigator-initiated study (“IIS”) evaluating extended HyBryte(TM) treatment.
• Soligenix announced the release of a publication describing the preclinical efficacy of CiVax(TM), a thermostabilized subunit vaccine against SARS-CoV-2.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases, recently announced its financial results for the first quarter of 2025, alongside a summary of the company’s latest accomplishments (https://ibn.fm/OMQmM). These milestones are representative of Soligenix’s continued commitment to advance its pipeline of therapeutic candidates, focusing on areas with significant unmet medical needs.

“Our strategic focus remains on advancing our clinical programs, and we anticipate several significant development milestones,” said Soligenix CEO and president Christopher J. Schaber, PhD. “These include top-line results in 2026 from our actively enrolling phase 3 confirmatory study of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans—a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as transformative, helping him confront trauma and save his marriage. Now in Congress, he’s pushing for science-based, medically supervised access to Schedule I drugs like ibogaine, psilocybin, and MDMA. Joined by fellow veterans in office, including Rep. Dan Crenshaw (R-Texas) and Rep. Jack Bergman (R-Mich.), Luttrell is helping lead legislative efforts to fund clinical trials through the VA and Pentagon, despite resistance from some conservatives and recent regulatory setbacks like the FDA’s rejection of an MDMA therapy from Lykos Therapeutics. 

Amid this shift, NRx Pharmaceuticals (NASDAQ: NRXP) and its subsidiary HOPE Therapeutics are emerging as leaders in veteran-focused psychedelic innovation. HOPE is developing ketamine-based treatments for acute suicidality and major depression and is building a nationwide network of…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (CSE: SUNN) posted fiscal Q3 results for the period ended March 31, 2025, showing year-to-date revenue of C$29.1 million versus C$50.4 million a year earlier, reflecting a shift toward long-term asset ownership over short-term EPC sales. The company reported a net loss of C$9 million compared to net income of C$5.5 million last year, driven by higher costs and reduced EPC activity. SolarBank highlighted a 395% increase in assets to C$194 million following the Solar Flow-Through Funds acquisition and secured a mandate letter with CIM Group for up to US$100 million in project financing for a 97 MW solar portfolio in the U.S., reinforcing its strategy to grow its independent power producer platform.

To view the full press release, visit https://ibn.fm/bWlJj

About SolarBank Corporation

SolarBank Corporation is an independent renewable and clean energy project developer and owner focusing on distributed and community solar projects in Canada and the USA. The Company develops solar, Battery Energy Storage System (BESS) and EV Charging projects that sell electricity to utilities, commercial, industrial, municipal and residential off-takers. The Company maximizes returns via a diverse portfolio of projects across multiple leading North America markets including projects with utilities, host off-takers, community solar, and virtual net metering projects. The Company has a potential development pipeline of over one gigawatt and has developed renewable and clean energy projects with a combined capacity of over 100 megawatts built. For more information, visit the company’s website at SolarBankCorp.com.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, is expanding its market presence and manufacturing capabilities through two new strategic partnerships. The company is collaborating with Charlotte FC to build brand visibility, particularly for its AI Tape and AVERSA(TM)—Nutriband’s proprietary technology that it believes has the potential to be the world’s first and only abuse deterrent patch platform for managing chronic pain. The company also deepened its collaboration with Kindeva Drug Delivery through an amended agreement focused on the development of Aversa(TM) Fentanyl, which combines Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. Through existing and new alliances with established brands in the health and wellness industry, Nutriband aims to diversify its revenue streams and reinforce its position as a leader in transdermal drug delivery solutions.

To view the full article, visit https://ibn.fm/2YofM

About Nutriband Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information about the company, visit www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted this week in a Zacks Small-Cap Research report that presented a favorable analysis, noting that the company’s Phase 3 cutaneous T-cell lymphoma (“CTCL”) study is continuing and that the trial has a high probability of success. 

According to the report, Soligenix is conducting a Phase 3 FLASH2 trial of HyBryte(TM) in patients with CTCL. The Zacks report noted that the FLASH2 trial is similar in design to the recently completed successful Phase 3 FLASH trial. The one key difference between the trials is that in the FLASH trial patients were treated for three cycles of six weeks each, with a two-week break in between cycles. The primary efficacy endpoint for the FLASH trial was measured after the first treatment cycle. 

“In the FLASH2 trial, patients will be treated for 18 consecutive weeks before the primary efficacy endpoint is assessed,” the report noted. “Based on the results from the FLASH trial, we believe the FLASH2 trial has a high probability of success, and we anticipate topline results in 2026.” 

To view the full report, visit https://ibn.fm/I58Bp 

About Soligenix Inc.  

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.  

The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).  

For further information, visit the company’s website at www.Soligenix.com. 

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

• The global powersports market is projected to grow to $60.51 billion by 2032.
• Recreational boating market size is expected to observe around a 10% CAGR from 2024 to 2032.
• Massimo Group has strategically positioned itself to leverage these market trends.

The powersports and recreational watercraft industries are experiencing a notable upswing, driven by consumers’ growing appetite for outdoor adventures and leisure activities. Amid this surge, Massimo (NASDAQ: MAMO), a Texas-based manufacturer and distributor, is emerging as a significant player, capitalizing on market trends and expanding its footprint in the sector.

The global powersports market, encompassing vehicles like ATVs, UTVs and bikes, was valued at $37.96 billion in 2023 and is projected to grow to $60.51 billion by 2032, reflecting a compound annual growth rate (“CAGR”) of 5.4% (https://ibn.fm/b205e). This growth is fueled by increasing consumer interest in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to MAMO are available in the company’s newsroom at https://ibn.fm/MAMO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

• Vivakor achieved substantial revenue growth in 2023, driven by expanded logistics operations and newly integrated midstream assets.
• The company operates a large-scale oilfield trucking fleet under long-term contracts, providing recurring revenue and service continuity.
• Its remediation facilities, once operational, will address a produced water treatment market forecast to reach $12.2 billion by 2028.
• Recent acquisitions have enhanced Vivakor’s infrastructure footprint and extended its service reach across key U.S. energy basins.
• The company’s integrated model aligns with industry trends favoring sustainability, compliance, and full-cycle fluid management.

Vivakor (NASDAQ: VIVK) is a vertically integrated energy infrastructure and environmental services company, focused on the transportation, storage, reuse, and remediation of oilfield fluids and waste. The company operates a large-scale oilfield trucking fleet, serving key U.S. energy regions, enabling end-to-end solutions for the handling of crude oil and produced water. Through long-term contracts and strategic asset positioning, Vivakor delivers critical services to upstream energy operators seeking efficient and environmentally responsible operations.

Vivakor’s vision is to become a leader in sustainable energy logistics and remediation by combining innovative infrastructure with environmentally conscious practices. The company’s integrated model allows it to optimize the flow and treatment of petroleum-based materials across the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to VIVK are available in the company’s newsroom at https://ibn.fm/VIVK

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

CNS Pharmaceuticals (NASDAQ: CNSP) reported a Q1 2025 net loss of $4.3 million, up from $3.5 million in the prior year period, as R&D spending increased to support data analysis for its Berubicin trial. The company remains focused on advancing TPI 287, a novel taxane with the potential to treat glioblastoma by crossing the blood-brain barrier. CNS has secured Orphan Drug Designation for TPI 287 and plans to initiate a Phase 2 study in recurrent GBM by late 2025. With $13.1 million in cash at quarter-end and an additional $5 million raised in May, the company expects to fund operations into the second half of 2026. 

To view the full press release, visit https://ibn.fm/2m0HS 

About CNS Pharmaceuticals Inc. 

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com. 

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

• The company posted record quarterly revenue of $15 million, up over 500% from Q1 2024.
• Gross profit surged to $13.9 million, driven by a high-margin Advantage™ quantum system sale.
• The company ended Q1 with $304.3 million in cash, its highest quarter-end balance in the company’s history.
• Customer count grew to 133, with 69 commercial users including 25 Forbes Global 2000 firms.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, reported a significant increase in revenue, gross profit, and cash reserves for the first quarter of fiscal 2025, enabled by the sale of a high-margin annealing quantum computing system. The results, detailed in a conference call hosted by CEO Dr. Alan Baratz and CFO John Markovich on May 8, signal the company’s continuing momentum in driving commercial adoption of quantum computing (https://ibn.fm/UoZWf).

Quarterly revenue came in at $15 million, a 509% increase from the same period last year, when the company reported $2.5 million. The growth was primarily attributed to a system sale recognized in the quarter, underscoring an additional revenue stream for the company beyond its traditional…

Read More>>

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2 systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Intelligent Bio Solutions (NASDAQ: INBS)  reported continued commercial growth, surpassing 450 active accounts with 35 added in fiscal Q3, driven by demand for its rapid, non-invasive fingerprint drug testing system. The company expanded into new sectors including luxury marine, retail, and waste management, while entering remote regions across Europe and Australia. INBS now operates in 24 countries and partners with 18 distributors across 19 nations. These milestones support the company’s global expansion strategy and position it for entry into the multi-billion-dollar U.S. testing market. 

To view the full press release, visit https://ibn.fm/XoMP5 

About Intelligent Bio Solutions Inc. 

Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. 

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to INBS are available in the company’s newsroom at https://ibn.fm/INBS

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (CSE: SUNN) President and CEO Dr. Richard Lu appeared on the GotStocks Podcast to discuss the company’s vertically integrated model and its $184 million portfolio of revenue-generating clean energy assets. Lu detailed how SolarBank develops, builds, owns, and operates distributed and community solar projects across Canada and the U.S., including partnerships with Honeywell and Qcells. He also highlighted a recent $100 million financing agreement with CIM Group to fund 97 MW of U.S. projects, positioning the company for continued long-term growth.

To view the full press release, visit https://ibn.fm/JdnZZ

About SolarBank Corporation

SolarBank Corporation is an independent renewable and clean energy project developer and owner focusing on distributed and community solar projects in Canada and the USA. The Company develops solar, Battery Energy Storage System (BESS) and EV Charging projects that sell electricity to utilities, commercial, industrial, municipal and residential off-takers. The Company maximizes returns via a diverse portfolio of projects across multiple leading North America markets including projects with utilities, host off-takers, community solar, and virtual net metering projects. The Company has a potential development pipeline of over one gigawatt and has developed renewable and clean energy projects with a combined capacity of over 100 megawatts built.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

NRx Pharmaceuticals (NASDAQ: NRXP) reported a Q1 2025 net loss of $5.5 million, down from $6.5 million in the same period last year, with operating losses narrowing to $3.8 million. The company advanced regulatory and commercial milestones for its two lead programs: NRX-100, a preservative-free IV ketamine formulation for suicidal depression now supported by an NDA fee waiver and new patent filing; and NRX-101, an oral treatment for bipolar depression with a PDUFA date anticipated before year-end. Subsidiary HOPE Therapeutics also gained momentum with $10.3 million in new acquisition funding to support a national psychiatry clinic rollup. NRx ended the quarter with $5.5 million in cash and expects its current capital and financing plans to support operations through year-end. 

To view the full press release, visit https://ibn.fm/AvI9R 

About NRx Pharmaceuticals, Inc. 

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. 

NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. 

For more information, please visit https://www.nrxpharma.com/ 

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Brera Holdings (NASDAQ: BREA) welcomed reports that Eagle Football Holdings, a $2 billion multi-club ownership group, is preparing to file for an IPO. Eagle’s portfolio includes stakes in Crystal Palace, Lyon, Botafogo, and Molenbeek. Brera Executive Chairman Dan McClory expressed support for the move, citing its potential to raise investor awareness of the MCO model and sports as an asset class. Brera, which completed its own Nasdaq listing in 2023, said it continues aligning with the sustainable football investment approach recently highlighted in The Wall Street Journal.

To view the full press release, visit https://ibn.fm/2g33t

About Brera Holdings PLC

Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.

For more information, visit the company’s website at www.BreraHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at http://ibn.fm/BREA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

NextPlat (NASDAQ: NXPL, NXPLW) reported Q1 2025 revenue of $14.5 million, down from $17.5 million in the prior year, driven by changes in 340B pharmacy agreements and prescription volume. Gross margin declined to 23.8%, while operating expenses fell 26% to $4.9 million due to reduced legal and non-recurring costs. Net loss narrowed to $1.3 million, or ($0.05) per share. The company ended the quarter with $17.7 million in cash and expanded its e-Commerce reach, including a 51% increase in recurring airtime revenue and growing OPKO product sales in China. Management remains focused on high-margin services and strategic healthcare growth.

To view the full press release, visit: https://ibn.fm/6s3JS

About NextPlat Corp

NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care Inc.

NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

• New online platform enables national reach with end-to-end purchasing and financing
• Management anticipates higher sales volume and deeper market penetration in 2025
• Powersports industry demand remains strong, supported by outdoor recreation and rural mobility trends

Massimo (NASDAQ: MAMO) is entering a new growth phase with the launch of a comprehensive digital retail platform. This move, announced in April 2025, is designed to simplify the purchasing process for its UTVs, ATVs, and mini-bikes, while expanding the company’s national sales footprint.

The platform enables customers to complete transactions online, including financing, titling, and checkout, providing a fully digital experience. Massimo expects this shift to unlock greater…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to MAMO are available in the company’s newsroom at https://ibn.fm/MAMO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Newton Golf Company (NASDAQ: NWTG) reported a 246% year-over-year revenue increase to $1.2 million in Q1 2025, driven by surging demand for its Newton Motion and Fast Motion shafts. Gross profit rose to $852,000 with margin expansion to 70%, while net loss narrowed to $0.5 million. More than 30 professionals have adopted Newton shafts, including 8 new players across major tours in Q1. The company also expanded into Japan, added key international distribution, and expects full-year revenue between $6.5 million and $7.0 million. 

To view the full press release, visit https://ibn.fm/cMPw9 

About Newton Golf 

At Newton Golf, we harness the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, our rebranding reflects our commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of our design process, we create precision-engineered golf clubs that deliver unmatched stability, control, and performance. Our mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics. 

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) will release its financial results for the quarter ended March 31, 2025, after market close today, May 15, and will host a webinar at 4:30 p.m. ET to provide a business update and discuss the quarterly performance. 

To view the full press release, visit https://ibn.fm/27iAY 

About SolarBank Corporation 

SolarBank Corporation is an independent renewable and clean energy project developer and owner focusing on distributed and community solar projects in Canada and the USA. The Company develops solar, Battery Energy Storage System (BESS) and EV Charging projects that sell electricity to utilities, commercial, industrial, municipal and residential off-takers. The Company maximizes returns via a diverse portfolio of projects across multiple leading North America markets including projects with utilities, host off-takers, community solar, and virtual net metering projects. The Company has a potential development pipeline of over one gigawatt and has developed renewable and clean energy projects with a combined capacity of over 100 megawatts built.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is scheduled to report its first quarter 2025 financial results after the market closes on Thursday, May 15. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company’s investor relations site or by dialing +1-800-717-1738 (U.S.) or +1-646-307-1865 (international). 

The earnings update comes shortly after news that NRx’s wholly owned subsidiary, HOPE Therapeutics, signed a definitive agreement to acquire Kadima Neuropsychiatry Institute in La Jolla, California. Kadima is a profitable clinic and leader in psychedelic and neuroplastic research, offering treatments for suicidal depression, PTSD and other CNS conditions. It is expected to serve as the model for HOPE’s national clinic rollout. 

To view the full press release announcing the Kadima agreement, visit https://ibn.fm/sxSUl 

About NRx Pharmaceuticals Inc.  

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.  

NRx has recently initiated a New Drug Application filing for NRX-100 (preservative-free IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the U.S. National Institutes of Health and newly obtained data from French health authorities, licensed under a data-sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the U.S. FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the U.S. Patent and Trademark Office.  

For further information, visit the company’s website at www.NRxPharma.com 

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Intelligent Bio Solutions (NASDAQ: INBS)  reported continued commercial growth, surpassing 450 active accounts with 35 added in fiscal Q3, driven by demand for its rapid, non-invasive fingerprint drug testing system. The company expanded into new sectors including luxury marine, retail, and waste management, while entering remote regions across Europe and Australia. INBS now operates in 24 countries and partners with 18 distributors across 19 nations. These milestones support the company’s global expansion strategy and position it for entry into the multi-billion-dollar U.S. testing market. 

To view the full press release, visit https://ibn.fm/XoMP5 

About Intelligent Bio Solutions Inc. 

Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. 

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to INBS are available in the company’s newsroom at https://ibn.fm/INBS

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on brain and central nervous system cancers, has priced a “reasonable best efforts” public offering with a single healthcare-focused institutional investor, raising approximately $5 million in gross proceeds. The offering includes 3,952,570 shares of common stock at $1.265 per share and accompanying Series F warrants to purchase an equal number of shares at $1.14 per share, exercisable immediately and valid for five years. A.G.P./Alliance Global Partners is acting as the sole placement agent. Proceeds will be used for working capital and general corporate purposes. Closing is expected on or about May 14, 2025. 

To view the full press release, visit https://ibn.fm/olurM 

About CNS Pharmaceuticals Inc. 

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com. 

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

HeartBeam (NASDAQ: BEAT) reported Q1 2025 results highlighted by successful completion of the VALID-ECG pivotal study, supporting its 510(k) submission for 12-lead ECG synthesis software and confirming productive ongoing FDA discussions. The company launched an Early Access Program, signed a strategic partnership with AccurKardia to integrate its FDA-cleared AccurECG(TM) software, added two new U.S. patents to bring its IP total to 20, appointed CEO Robert Eno to its board, and raised $11.5 million through a public offering to support commercialization plans.

To view the full press release, visit https://ibn.fm/Gnz4f

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com .

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

• The opioid epidemic has prompted a re-evaluation of pain-management strategies, highlighting the importance of balancing effective treatment with abuse prevention
• Nutriband’s AVERSA(TM) Fentanyl represents a significant advancement in this domain
• The company’s strategic development of AVERSA Fentanyl follows a structured pharmaceutical lifecycle

As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient access to necessary medications. Nutriband’s development of AVERSA(TM) Fentanyl, an abuse-deterrent transdermal patch, exemplifies this forward-thinking approach (https://ibn.fm/jhHMY).

The opioid epidemic has prompted a reevaluation of pain-management strategies, highlighting the importance of balancing effective treatment with abuse prevention. Traditional methods often involve limiting prescriptions, which can inadvertently hinder patients with…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Mullen Automotive (NASDAQ: MULN), an electric vehicle manufacturer, announced it has executed a settlement agreement with GEM Yield Bahamas Limited and GEM Global Yield LLC SCS, resolving a four-year legal dispute. Under the agreement, GEM has a 55-day due diligence period—subject to extension—to evaluate the transfer of Mullen’s Mishawaka assets in full satisfaction of the judgment. All collection activities will be suspended during this period. Mullen stated it remains focused on expanding its Tunica, Mississippi, manufacturing operations to meet growing demand across its EV product lines. 

To view the full press release, visit https://ibn.fm/sOuN2 

About Mullen Automotive Inc. 

Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com. 

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN 

About GreenCarStocks

GreenCarStocks (“GCS”) is a specialized communications platform with a focus on electric vehicles (“EVs”) and the green energy sector. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled recognition and brand awareness. GCS is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from GreenCarStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the GreenCarStocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

GreenCarStocks
Austin, Texas
www.GreenCarStocks.com
512.354.7000 Office
[email protected]

GreenCarStocks is powered by IBN

CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the blood-brain barrier and demonstrated encouraging results in a Phase 1 glioblastoma trial, including 3 complete and 9 partial responses among 23 evaluable patients. The company plans to initiate a Phase 2 study by year-end 2025 and highlighted the potential benefits of Orphan status, including seven years of market exclusivity upon approval.

To view the full press release, visit https://ibn.fm/7O5UX

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company delivering rapid, non-invasive testing solutions, reported a 20% sequential revenue increase to $728,867 in fiscal Q3 2025, driven by growth in cartridge sales, which now account for 58% of total revenue and strengthen its recurring revenue model. Gross profit surged 91% year-over-year to $341,368, while net loss narrowed by $434,141 to $2.54 million. INBS added 35 new accounts, bringing its active customer base to over 450, and continued expanding internationally through partnerships and multilingual system upgrades. The company also secured its sixth U.S. patent and advanced regulatory efforts across key global markets.

To view the full press release, visit https://ibn.fm/V56hu

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to INBS are available in the company’s newsroom at https://ibn.fm/INBS

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Disseminated on behalf of SolarBank Corporation

• SolarBank and CIM Group have announced a US$100 million financing deal for a portfolio of U.S. solar energy projects totaling 97 MW.
• The deal is structured as a preferred equity investment at the project level, preserving SolarBank’s share capital, with CIM receiving a 3% annual coupon and retaining full ownership of transferred investment tax credits.
• SolarBank expects to maintain majority ownership of the 21-project portfolio post-financing, supporting SolarBank’s shift toward becoming a long-term solar asset owner in the U.S.

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., has announced a US$100 million project-based financing with infrastructure investor CIM Group to fund a 97 MW portfolio of solar energy projects in the United States. The deal marks a significant step in SolarBank’s evolution from solar developer to long-term asset owner, offering equity-style exposure to U.S. renewable energy growth without issuing new shares (https://ibn.fm/J7XIZ).

The financing will be structured as a preferred equity investment by CIM into a newly formed entity, New HoldCo. That entity will operate as a joint venture between CIM and Abundant Solar Power (“ASP”), a…

Read More>>

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a definitive agreement to acquire the Kadima Neuropsychiatry Institute. Kadima, a leading California clinic for interventional psychiatry, offers treatments such as ketamine, Spravato, transcranial magnetic stimulation (TMS), and medication management for CNS disorders including suicidal depression and PTSD. The clinic is profitable and expected to serve as the clinical model for future HOPE clinics. Dr. David Feifel, Kadima’s founder and a nationally recognized leader in interventional psychiatry, will join HOPE as its first Chief Medical Innovation Officer following the closing of the acquisition, which remains subject to customary conditions and financing.

To view the full press release, visit https://ibn.fm/T1WlB

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

For more information, please visit https://www.nrxpharma.com/

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

NRx Pharmaceuticals (NASDAQ: NRXP) announced it will release its first quarter 2025 financial results after market close on Thursday, May 15, 2025. The company will host a conference call at 4:30 p.m. ET the same day to discuss the results and provide a corporate update. 

To view the full press release, visit https://ibn.fm/f5iwL 

About NRx Pharmaceuticals, Inc. 

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. 

NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. 

For more information, please visit  https://www.nrxpharma.com/

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, posted record first quarter 2025 revenue of $15 million, up 509% from the prior year. Business and financial results for the quarter included the first Advantage™ annealing quantum computer sale and publication of breakthrough research demonstrating quantum supremacy on a real-world problem.

The company ended the quarter with a record $304.3 million in cash on hand. Consolidated gross margin rose to 92.5%, with the company citing sufficient liquidity to reach profitability.

To view the full press release, visit https://ibn.fm/oSLnE

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2™ systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (CSE: SUNN) has filed a final short form base shelf prospectus with Canadian securities regulators, replacing its previous version set to expire in June 2025. The new Shelf Prospectus allows the company to offer up to C$200 million in securities—including common shares, debt instruments, warrants, and units—over the next 25 months. A corresponding Form F-10 registration has been filed with the U.S. SEC but is not yet effective. Proceeds from any future offerings will support business development, working capital, debt repayment, capital programs, and potential

To view the full press release, visit https://ibn.fm/9Y04S

About SolarBank Corporation

SolarBank Corporation is an independent renewable and clean energy project developer and owner focusing on distributed and community solar projects in Canada and the USA. The Company develops solar, Battery Energy Storage System (BESS) and EV Charging projects that sell electricity to utilities, commercial, industrial, municipal and residential off-takers. The Company maximizes returns via a diverse portfolio of projects across multiple leading North America markets including projects with utilities, host off-takers, community solar, and virtual net metering projects. The Company has a potential development pipeline of over one gigawatt and has developed renewable and clean energy projects with a combined capacity of over 100 megawatts built.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

• Nutriband’s AVERSA(TM) technology is advancing toward commercialization as the first abuse-deterrent transdermal fentanyl patch
• Recent FDA regulatory changes underscore the urgent need for safer opioid delivery methods and responsible prescribing
• Strategic milestones with partner Kindeva and a strengthened global IP portfolio position Nutriband for long-term growth

A Market Demanding Safer Opioid Solutions

The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid manufacturers are now required to include prepaid mail-back envelopes for safe disposal of unused medications, while enhanced boxed warnings on opioid labels further reinforce the dangers of misuse, addiction, and overdose.

These regulatory shifts reflect a growing emphasis on not only expanding non-opioid options but also improving the safety of existing opioid therapies, creating a compelling market opportunity for…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• A growing number of golfers competing at the highest levels of senior professional golf are making the switch to Newton’s innovative equipment.
• The tech behind the shaft is key to its performance.
• The benefits of Newton Motion shafts are not exclusive to seasoned professionals.

Newton Golf Company (NASDAQ: NWTG) Motion shafts are garnering significant attention for the impressive performance benefits they offer, particularly among players on the Champions Tour. A recent Golf.com article praised the high-quality construction of these shafts and noted that a growing number of golfers competing at the highest levels of senior professional golf are making the switch to Newton’s innovative equipment (https://ibn.fm/jj5ki). This surge in popularity highlights Newton Golf’s commitment to pushing the boundaries of golf shaft technology, offering players a more consistent, powerful and reliable swing.

“If you’ve been paying attention to what’s in players’ bags on the Champions Tour lately, you’ve probably noticed something sneaky-good popping up more and more: Newton Motion shafts,” the article stated. “In a sea of ‘proprietary blends’ and ‘made for’ composites, Newton shafts aren’t just your average…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharma company focused on inflammation and immunology treatments and CDMO services, reported a $4.8 million net gain for 2024, reversing a $6.5 million loss in 2023. The improvement was largely due to $14.8 million in financial income from a loan-to-equity conversion. The company posted $658,000 in revenue—its first ever—from its CDMO unit. R&D expenses remained steady at $5.6 million, while G&A costs dropped to $2.6 million. Cash and equivalents totaled $1.9 million at year-end. 

To view the full press release, visit https://ibn.fm/CNAN2 

About Scinai Immunotherapeutics Ltd. 

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com. 

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

Newton Golf Company (NASDAQ: NWTG) Co-Founder and CTO Aki Yorihiro appeared on the latest episode of IBN’s TechMediaWire Podcast to discuss the company’s Fast Motion Shaft, now in use on the PGA TOUR Champions, LPGA, and Korn Ferry Tours. Yorihiro outlined how the shaft’s speed-optimized design and Newton’s proprietary fitting system are reshaping performance standards for players of all types. With over 30 tour pros already using Newton shafts, the company continues to push innovation in golf technology through science-backed engineering and user-centered design.

To view the full press release, visit https://ibn.fm/0Jk2o

About Newton Golf

At Newton Golf, we harness the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, our rebranding reflects our commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of our design process, we create precision-engineered golf clubs that deliver unmatched stability, control, and performance. Our mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, announced that it will participate in several upcoming investor conferences. These include the Needham Technology, Media & Consumer Virtual Conference on May 9 and 12, the J.P. Morgan Global TMC Conference on May 13 in Boston, the J.P. Morgan Virtual Quantum Conference on May 20, the B. Riley Institutional Investor Conference on May 21 in Los Angeles, the Stifel 2025 Boston Cross Sector Conference on June 3-4, and the ROTH London Conference on June 24-26.

Interested parties are advised to contact the respective investment banks to register or arrange meetings.

To view the full press release, visit https://ibn.fm/OZyCW

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage^TM quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2^TM systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Disseminated on behalf of SolarBank Corporation

• SolarBank plans to develop a 7.2 MW DC ground-mount solar project in upstate New York, part of a growing pipeline of SolarBank developments in the area.
• The project will operate under a community solar model, with customer acquisition managed by Solar Simplified, and is expected to power approximately 850 homes.
• In addition, the new development will participate in New York’s VDER rate program and may qualify for NYSERDA incentives.

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., announced the development of a new 7.2 megawatt DC ground-mount solar project in upstate New York. The Glor Rd project, as it is known, adds to a string of solar installations that the company is developing across the region (https://ibn.fm/Z98Pf).

The project will operate under New York’s community solar framework, which allows residents and renters to subscribe to clean energy without installing solar panels on their own properties. Once online, the…

Read More>>

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Soligenix Inc. (NASDAQ: SNGX) Chairman and CEO Dr. Christopher Schaber joined IBN’s BioMedWire Podcast to discuss the company’s two-pronged business model, robust late-stage pipeline, and ongoing clinical trials. Schaber emphasized Soligenix’s focus on rare disease therapeutics and its Public Health Solutions segment, which has received over $60 million in non-dilutive U.S. government funding. He also outlined near-term milestones, including a confirmatory Phase 3 trial, active partnership discussions, and continued pursuit of strategic opportunities. 

To view the full press release, visit https://ibn.fm/5HqfY 

About Soligenix, Inc. 

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet’s Disease. 

Our Public Health Solutions business segment includes development programs for RiVax ^®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax ^®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA). 

For more information, visit the company’s website at at https://www.soligenix.com

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

• INBS offers a patented, non-invasive testing solution positioned to disrupt a global drug screening market projected to reach $14.9 billion by 2030.
• The company is revenue-generating, with 148% year-over-year growth in FY 2024 and 450+ active customer accounts.
• Its Intelligent Fingerprinting system provides rapid, on-site results with a lower cost and higher convenience compared to traditional methods.
• The Intelligent Fingerprinting Drug Screening System is already in commercial use internationally, and a U.S. product launch is planned for 2025, with FDA 510(k) clearance in process and new patent protections underway.
• INBS is led by a seasoned executive team with global healthcare and commercialization experience.

Intelligent Bio Solutions (NASDAQ: INBS) is a medical technology company pioneering rapid, non-invasive diagnostics through its proprietary Intelligent Fingerprinting Drug Screening System. By utilizing fingerprint sweat analysis, the company offers a cost-effective, hygienic solution to detect recent drug use — targeting substances commonly found in workplace settings such as opiates, cocaine, methamphetamine, and cannabis. This innovative approach positions INBS to transform drug testing protocols, particularly in industries where safety and speed are mission critical.

The company’s vision is to redefine drug screening by removing the pain points of traditional testing methods, including biohazardous waste, privacy concerns, and long result turnaround times. With results in under 10 minutes and no need for gender-specific collectors or laboratory facilities, the system…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to INBS are available in the company’s newsroom at https://ibn.fm/INBS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) today announced it will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. CEO Dr. Richard Lu will be available for one-on-one investor meetings from 9 a.m. to 3 p.m. ET. 

To view the full press release, visit https://ibn.fm/Kw5Bd 

About SolarBank Corporation 

SolarBank Corporation is an independent renewable and clean energy project developer and owner focusing on distributed and community solar projects in Canada and the USA . The Company develops solar, Battery Energy Storage System (BESS) and EV Charging projects that sell electricity to utilities, commercial, industrial, municipal and residential off-takers. The Company maximizes returns via a diverse portfolio of projects across multiple leading North America markets including projects with utilities, host off-takers, community solar, and virtual net metering projects. The Company has a potential development pipeline of over one gigawatt and has developed renewable and clean energy projects with a combined capacity of over 100 megawatts built.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) has entered into a mandate letter with CIM Group to secure up to $100 million in project-level preferred equity financing for 97 MW of solar power projects in the U.S. The financing, structured through a joint venture with SolarBank subsidiary Abundant Solar Power Inc., will not involve the issuance of new SolarBank shares. CIM will acquire non-convertible preferred equity in the venture, with SolarBank retaining majority ownership of the 21 projects. The deal includes a revenue-sharing model, tax credit transfers, and redemption rights after a five-year holding period, pending final documentation and development milestones. 

To view the full press release, visit https://ibn.fm/WkuKS 

About SolarBank Corporation 

SolarBank Corporation is an independent renewable and clean energy project developer and owner focusing on distributed and community solar projects in Canada and the USA . The Company develops solar, Battery Energy Storage System (BESS) and EV Charging projects that sell electricity to utilities, commercial, industrial, municipal and residential off-takers. The Company maximizes returns via a diverse portfolio of projects across multiple leading North America markets including projects with utilities, host off-takers, community solar, and virtual net metering projects. The Company has a potential development pipeline of over one gigawatt and has developed renewable and clean energy projects with a combined capacity of over 100 megawatts built.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Mullen Automotive (NASDAQ: MULN) announced that its subsidiary, Bollinger Motors, has delivered a Bollinger B4 all-electric Class 4 commercial vehicle to the Lower East Side Ecology Center in New York City. Funded by the NYC Council, the truck will support composting and environmental programs as the LES Ecology Center’s first EV. The B4, equipped with a 158-kWh battery, 185-mile range, and a 16-foot dry box with power lift gate, is designed for urban operations and sustainability-focused fleets.

To view the full press release, visit https://ibn.fm/xyfbw

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About GreenCarStocks

GreenCarStocks (“GCS”) is a specialized communications platform with a focus on electric vehicles (“EVs”) and the green energy sector. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled recognition and brand awareness. GCS is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from GreenCarStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the GreenCarStocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

GreenCarStocks
Austin, Texas
www.GreenCarStocks.com
512.354.7000 Office
[email protected]

GreenCarStocks is powered by IBN

HeartBeam (NASDAQ: BEAT), a medical technology company advancing personalized cardiac care, announced the issuance of two new U.S. patents that strengthen its intellectual property position. The first patent covers the company’s credit card-sized, cable-free 3D ECG device, which enables real-time cardiac monitoring and symptom capture. The second patent protects its rhythm analysis algorithm, which identifies arrhythmias using continuous signal input and prompts users to collect 3D ECG data when anomalies are detected. These additions expand HeartBeam’s patent count to 20 issued and 34 others pending or allowed, reinforcing its platform ahead of future product extensions and FDA review of its 12-lead ECG synthesis software. 

To view the full press release, visit https://ibn.fm/Nyzpu 

About HeartBeam Inc. 

HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com . 

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

HeartBeam (NASDAQ: BEAT) a medical technology company advancing personalized cardiac care, has appointed Chief Executive Officer Robert Eno to its Board of Directors, expanding the board from eight to nine members. Eno, who joined the company as president in January 2023 and became CEO in October 2024, brings over 30 years of medtech leadership experience, including launching disruptive technologies. His appointment comes as the company prepares for the commercial launch of its 3D ECG technology, pending FDA clearance of its 12-lead ECG synthesis software. 

To view the full press release, visit https://ibn.fm/7SiVW 

About HeartBeam Inc. 

HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com . 

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

Massimo (NASDAQ: MAMO) is making strategic moves to actively enhance its position in the powersports and recreational vehicle industry. The company is expanding its retail partnership with Rural King to include a wider range of products, while optimizing logistics with a new distribution center in Illinois and mitigating tariff risks and enhancing quality with Texas-based golf cart production. Massimo is also boosting manufacturing efficiency through robotics and launching new models in its popular UTV line, including the Buck 550-6 Crew and winter-ready T-Boss editions. These initiatives reflect a bold, proactive strategy centered on growth, innovation and responsiveness to consumer demands, all while skillfully navigating industry challenges.

To view the full article, visit https://ibn.fm/pWaK6

About Massimo Group

Massimo Group is a manufacturer and distributor of powersports vehicles and pontoon boats. Founded in 2009, Massimo Motor believes it offers some of the most value packed UTVs, off-road, and on-road vehicles in the industry. The company’s product lines include a wide selection of farm and ranch tested utility UTVs, recreational ATVs, and Americana style mini-bikes. Massimo Marine manufactures and sells pontoon and tritoon boats with a dedication to innovative design, quality craftsmanship, and great customer service. Massimo Group is also developing electric versions of UTVs, golf-carts and pontoon boats. The company’s 376,000 square foot factory is in the heart of the Dallas / Fort Worth area of Texas in the city of Garland. For more information, visit massimomotor.com and massimomarine.com.

NOTE TO INVESTORS: The latest news and updates relating to MAMO are available in the company’s newsroom at https://ibn.fm/MAMO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Disseminated on behalf of SolarBank Corporation 

• SolarBank is developing a 4.584 MW DC ground-mount solar project in upstate New York, projected to power 540 homes.
• The Forest Hill Rd project will operate under New York’s community solar framework and benefit from VDER compensation and NYSERDA incentives.
• Solar Simplified will handle subscriber management, allowing SolarBank to focus on development and expansion.
• The company is not presently importing solar panels from the four countries impacted by the April 21, 2025, U.S. Department of Commerce Tariff announcement.

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., announced that it was moving forward with the development of its Forest Hill Rd solar project in upstate New York. The 4.584 megawatt DC installation will operate as a community solar facility, contributing renewable energy to the local grid and offering cost savings to approximately 540 homes (https://ibn.fm/AB4zH).

The company announced that the site lease has been secured and an interconnection study is currently underway. If successful, SolarBank will proceed with permitting and financing. The project is expected to qualify for compensation under the Value of Distributed Energy Resources (“VDER”) framework, a…

Read More>>

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharma company, has filed a patent application for NRX-100, its preservative-free intravenous ketamine formulation targeting suicidal depression. The patent, which includes 20 claims, could provide exclusivity through 2045 if granted. NRX-100 is designed without benzethonium chloride or other preservatives linked to toxicity and has shown room temperature shelf stability—potentially qualifying it for FDA Orange Book listing. The filing supports the company’s NDA submission strategy and complements the FDA Fast Track Designation of companion drug NRX-101.

To view the full press release, visit https://ibn.fm/X8uSQ

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

For more information, please visit https://www.nrxpharma.com/

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/TCKxC

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

• The global rare disease treatment market was estimated at $195.2 billion in 2024 and is anticipated to expand at a CAGR of 11.6% by 2030.
• SNGX’s HyBryte(TM) has demonstrated positive results in a study testing its use for patients with early-stage CTCL.
• HyBryte(TM) is a novel therapy based on photodynamic therapy, which combines light and a photosensitizer to target and destroy cancer cells.

The development of treatments for rare diseases remains one of the most pressing challenges in modern medicine. Despite significant advancements in healthcare, many rare diseases still have no approved treatments, and patients often face grim prospects. The market for treatments in this space is substantial, as rare diseases collectively affect millions of people worldwide. Among those working tirelessly to fill these gaps is Soligenix (NASDAQ: SNGX), a biopharmaceutical company that is leading the way with innovative therapies for rare and difficult-to-treat diseases, particularly early-stage cutaneous T-cell lymphoma, a rare form of cancer that affects the skin.

The global market for rare disease treatments is growing at an impressive rate. According to a report by Grand View Research, the global rare disease treatment market was estimated at $195.2 billion in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI) will host a webinar May 7 at 11:30 a.m. EST to discuss the treatment potential of Pincell’s novel monoclonal antibody, PC111, for rare skin conditions Pemphigus Vulgaris and SJS/TEN. The session will cover unmet medical needs, PC111’s mechanism targeting soluble Fas ligand, and development plans. The event follows Scinai’s March agreement to acquire Pincell and a related €12 million grant application under Poland’s FENG program. Panelists include executives from Scinai and Pincell, with a live Q&A segment. 

To view the full press release, visit https://ibn.fm/BunpC 

About Scinai Immunotherapeutics Ltd. 

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com. 

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

HeartBeam (NASDAQ: BEAT) will host a conference call on May 13 at 4:30 p.m. Eastern to discuss financial results for the first quarter ended March 31, 2025. CEO Robert Eno and CFO Timothy Cruickshank will lead the call, which will include updates on regulatory progress, commercial-readiness efforts, and upcoming milestones. A corresponding press release and presentation will be available on the company’s investor relations website.

To view the full press release, visit https://ibn.fm/cogtu

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com .

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Nutriband (NASDAQ: NTRB) has released a shareholder letter from CEO Gareth Sheridan outlining key achievements in 2024 and plans for 2025, centered on advancing its AVERSA™ abuse-deterrent transdermal technology. The company is transitioning from feasibility to commercial development of AVERSA Fentanyl in partnership with Kindeva Drug Delivery, targeting a pivotal Human Abuse Liability clinical trial and NDA filing. AVERSA Fentanyl and AVERSA Buprenorphine could reach peak annual sales of up to $200 million and $130 million respectively. Nutriband also expanded its global patent portfolio to 46 countries and raised $8.4 million in a non-brokered placement. The company expects continued revenue growth in 2025 from its Pocono Pharma subsidiary, driven by its partnership with KT Tape.  

To view the full article, visit https://ibn.fm/NGtih 

About Nutriband Inc. 

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information about the company, visit www.Nutriband.com. 

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

Brera Holdings (NASDAQ: BREA) reaffirmed its commitment to a sustainable, community-focused multi-club ownership model, drawing parallels to trends highlighted in a recent Wall Street Journal article on the rise of U.S.-led football investments. The Company emphasized its strategic acquisition of Juve Stabia, now contending for Serie A promotion, as a prime example of its ladder-climbing approach. As the first publicly traded MCO group, Brera promotes long-term value creation by integrating local engagement, operational discipline, and public market transparency across its expanding global portfolio.

To view the full press release, visit https://ibn.fm/1b3df

About Brera Holdings PLC

Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.

For more information, visit the company’s website at www.BreraHoldings.com

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at least one dose across four dosing levels, with no significant toxicities observed. Eight patients remain in the trial, with two showing stable disease after seven months. Early PK/PD data indicate target engagement and a dose-response relationship consistent with preclinical findings. The results support advancing the trial to Phase 1b for expanded safety and anti-tumor activity evaluation. 

To view the full press release, visit https://ibn.fm/OjVf3 

About TransCode Therapeutics 

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers. 

For more information, please visit https://ir.transcodetherapeutics.com/

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

• Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year Awards
• The CEO’s international perspective and expertise were further validated when he was featured in a recent BBC News article
• Chairman Serguei Melnik also participated in a market interview where he spoke about Nutriband’s mission, achievements and plans for the future

Nutriband (NASDAQ: NTRB) is earning widespread recognition for the board’s leadership, expertise and innovation across a variety of platforms. Sheridan has recently been acknowledged in several high-profile ways that affirm his growing influence as a respected professional in the healthcare and business sectors. From being named a finalist for the prestigious EY Entrepreneur of the Year Awards to providing key insights in a BBC News feature on Irish companies operating internationally and sharing their strategic vision in a wide-ranging interview, NTRB’s voice is increasingly shaping discussions around entrepreneurship, innovation and the future of healthcare.

In a major milestone for his career, Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year Awards (https://ibn.fm/U1Tpb). He has been recognized in the International Category, which honors entrepreneurs whose companies have a significant footprint beyond their…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs, just recorded the highest market value increase for its portfolio club, S.S. Juve Stabia S.r.l
• The club posted a 36.9% increase since March 15, 2025, an increase from €11.78 million to €16.13 million
• For Brera, this growth demonstrates the swift impact of its ownership, and the club’s growing competitiveness, on and off the pitch

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, just crossed a significant milestone with S.S. Juve Stabia S.r.l. Dubbed “The Second Team of Naples,” Juve Stabia just recorded the highest market value increase in Italy’s Serie B, according to Transfermarkt. This demonstrates Brera’s ownership’s swift impact on the club, pointing to the latter’s growing competitiveness, on and off the pitch.

“This extraordinary growth reflects both the untapped potential of Juve Stabia and Brera’s…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”) for HyBryte(TM), a novel photodynamic therapy designed to treat early-stage cutaneous T-cell lymphoma (“CTCL”). Building on the success of a prior phase 3 trial, HyBryte(TM)—which uses synthetic hypericin activated by safe visible light—offers a potentially game-changing approach by providing a noninvasive, well-tolerated alternative that targets malignant T-cells with precision. With patient enrollment underway and interim analysis expected in early 2026, the study is designed to potentially meet the stringent requirements of regulatory agencies in order to strengthen the case for HyBryte(TM) as a commercially available treatment. This milestone emphasizes Soligenix’s broader strategy of using innovative therapeutic approaches to tackle rare and difficult-to-treat diseases. The progress of HyBryte(TM) also underscores the importance of photodynamic therapy as a new and effective modality that could potentially be applied to other dermatological and oncological conditions.

To view the full article, visit https://ibn.fm/Kw75K

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.

Soligenix’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of its vaccine programs incorporates the use of the company’s proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).

For further information regarding Soligenix, visit the company’s website at www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

• Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs, just recorded the highest home attendance of the season for its S.S. Juve Stabia S.r.l football club competing in Italy’s Serie B
• The derby match against Salernitana, held on April 5, posted a crowd of 7,000 fans at Stadio Romeo Menti in Castellammare di Stabia, just 100 shy of a full sell-out
• For Brera, this milestone pointed to the club’s potential, along with its trajectory to become a playoff-competitive football club and a globally relevant brand
• It also affirmed the company’s continued push for matchday monetization, a key priority for its revenue-generation activities for the 2025-26 season

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, just recorded the highest home attendance of the season for its S.S. Juve Stabia S.r.l football club, “The Second Team of Naples,” a significant milestone for the company. Its management continues to push for matchday monetization, a key driver for the 2025-26 season revenue-generation (https://ibn.fm/yILdD).

On April 5, in a match against Salernitana, Juve Stabia posted a crowd of 7,000 fans, just 100 seats shy of a full sell-out given the stadium’s 7,100 capacity. For the club, this attendance not only delivered a vibrant atmosphere but also showed passion for the game, which was a huge morale boost for the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

HeartBeam (NASDAQ: BEAT) announced that its synthesized 12-lead ECG technology met clinical endpoints in the VALID-ECG pivotal study, achieving a 93.4% diagnostic agreement with standard 12-lead ECGs for arrhythmia assessment. Results were presented by Dr. Thomas Deering of Piedmont Heart Institute during the Heart Rhythm Society’s annual conference. HeartBeam’s 3D ECG technology, designed to fit into a credit card-sized device, aims to bring hospital-grade cardiac insights to patients anywhere, with commercialization planned following anticipated FDA clearance.

To view the full press release, visit https://ibn.fm/ABvdX

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com .

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Disseminated on behalf of SolarBank Corporation 

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) announced plans to develop the Glor Rd project, a 7.2 MW DC ground-mount solar installation in upstate New York. With a secured site lease and an interconnection study underway, the project will operate under New York’s VDER rate mechanism and is expected to qualify for NYSERDA NY-Sun Program incentives. Once completed, the project will provide community solar benefits to local residents, offering clean energy access without the need for personal panel installations. Solar Simplified will manage customer-facing activities to support full subscription and maximize revenue. 

To view the full press release, visit https://ibn.fm/2pHI4 

About SolarBank Corporation 

SolarBank Corporation is an independent renewable and clean energy project developer and owner focusing on distributed and community solar projects in Canada and the USA . The Company develops solar, Battery Energy Storage System (BESS) and EV Charging projects that sell electricity to utilities, commercial, industrial, municipal and residential off-takers. The Company maximizes returns via a diverse portfolio of projects across multiple leading North America markets including projects with utilities, host off-takers, community solar, and virtual net metering projects. The Company has a potential development pipeline of over one gigawatt and has developed renewable and clean energy projects with a combined capacity of over 100 megawatts built.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Newton Golf Company (NASDAQ: NWTG) announced the launch of its newest shaft family, Newton Fast Motion, now available for purchase at a suggested retail price of $325. The lighter, Tour-proven shaft is engineered to deliver exceptional precision and enhanced swing speed, building on the company’s four core technologies: Elongated Bend Profile, Kinetic Energy Storage, Symmetry 360 Construction and Variable Bend Profile. The Fast Motion series, constructed with advanced high-modulus Toray carbon fibers and featuring a distinctive red-to-gold finish, has already seen adoption by more than 30 professionals across the PGA TOUR Champions and LPGA Tour. Following 887% revenue growth in FY2024, Newton Golf expects the Fast Motion series to further accelerate its momentum in 2025.

To view the full press release, visit https://ibn.fm/EVqqq

About Newton Golf

At Newton Golf, we harness the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, our rebranding reflects our commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of our design process, we create precision-engineered golf clubs that deliver unmatched stability, control, and performance. Our mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, was featured in a recent article that discussed its innovative AVERSA(TM) abuse-deterrent technology and business model. “AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China, with recent extensions into Macao,” the article reads. 

“The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.” 

To view the full article, visit https://ibn.fm/aeURJ 

About Nutriband Inc. 

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information about the company, visit www.Nutriband.com. 

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

• On April 13, a match between SS Juve Stabia S.r.l and Cremonese was aired live with English-language commentary in the U.S., Canada, and the U.K. through Destination Calcio. Juve Stabia is a portfolio club of Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs
• The broadcast marked a key milestone for the club and the company in growing their global recognition and key English-speaking markets
• Brera is optimistic that initiatives such as these will expand the club’s footprint beyond Italy, ultimately reaching a broader base of international supporters
• In addition, its management is confident that it will further showcase the energy and ambition of the team to new audiences, including Italians living abroad

Brera Holdings (NASDAQ: BREA), an Ireland-based international holding company focused on building a global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) model, announced that on April 13, 2025, its portfolio club SS Juve Stabia S.r.l.’s match against Cremonese was broadcast live in the United States, Canada, and the United Kingdom. This broadcast was conducted in partnership with Destination Calcio, with full English commentary, marking a key milestone for the club and the company in growing global recognition (https://ibn.fm/9PTJw).

The match was hosted by fourth-ranked Cremonese, and Juve Stabia played to a 1-1 draw. SS Juve Stabia currently ranks 5^th in Serie B and recently made headlines for achieving the highest squad value growth in the league at 36.8% since mid-March. The club has also posted a recent season-high home…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

• D-Wave and Japan Tobacco’s pharmaceutical division completed a proof-of-concept project aimed at speeding up and improving the design of small molecule pharmaceuticals.
• D-Wave’s annealing quantum computer was used to train large language models within Japan Tobacco’s AI framework.
• The quantum-hybrid application outperformed classical methods in generating valid and drug-like molecules.
• Japan Tobacco plans to further pursue Quantum AI in molecular design following these early results.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the pharmaceutical division of Japan Tobacco Inc. (“JT”), have announced the successful completion of a proof-of-concept project applying quantum computing and artificial intelligence (“AI”) to drug discovery. The project demonstrated that a hybrid quantum-classical system outperformed classical methods in generating potential drug compounds (https://ibn.fm/5sTUn).

The project used D-Wave’s annealing quantum computer to enhance the training of large language models (“LLMs”) for chemical structure generation. LLMs, which are foundational to modern generative AI, were integrated into JT’s drug discovery process to explore chemical space and propose…

Read More>>

About D-Wave Quantum Inc. 

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage^TMquantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2 systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com. 

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Newton Golf Company Inc. (NASDAQ: NWTG), a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design, has seen its Newton Motion shafts rapidly gain popularity on the Champions Tour, recently earning a feature on Golf.com for their innovative performance benefits tailored to senior players. The shafts utilize a unique variable stiffness profile—more flexible in the midsection and stiffer at the tip and butt ends—resulting in improved energy transfer, higher launch angles, and increased distance. These design advantages have made them a go-to choice for many veteran professionals seeking more consistency and power in their drives.

To read the full Golf.com feature, visit https://ibn.fm/xGPt9

About Newton Golf Company Inc.

Newton Golf harnesses the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, the company’s rebranding reflects its commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of its design process, Newton Golf creates precision-engineered golf clubs that deliver unmatched stability, control, and performance. The company’s mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics.

For more information, visit the company’s website at www.NewtonGolfIR.com

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

• The sport offers a unique blend of physical activity, mental challenge and social interaction.
• Newton Golf focuses on creating products that enhance performance and enjoyment for golfers of all skill levels.
• In 2025, Newton Golf is poised to make significant strides in the industry.

Golf has experienced a remarkable resurgence in recent years, evolving from a traditional pastime into a dynamic sport embraced by a diverse and growing audience. According to the National Golf Foundation, a record 47.2 million Americans aged six and older engaged in golf activities in 2024, combining both on-course and off-course participation. This surge includes 28.1 million on-course players and 19.1 million who enjoyed golf through driving ranges, simulators, and entertainment venues like Topgolf (https://ibn.fm/JSo6U).

A key part of this growth is the increasing involvement of women in the sport. Women account for approximately 20% of the U.S. golf equipment market, representing a significant portion of total golf equipment sales, with women spending an estimated $1 billion annually on equipment. While men are…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, is featured in a new Benzinga video detailing clinical progress for its lead candidate HyBryte™, which achieved a 75% response rate in a trial for cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer. The trial is supported by funding from a U.S. Food and Drug Administration’s Orphan Products Development Grant and showcases HyBryte’s™ potential as a first-in-class, light-activated, non-invasive therapy.

HyBryte™ is a first-in-class photodynamic therapy activated by safe visible light and has previously received Orphan Drug and Fast Track designations. Soligenix plans to continue advancing regulatory discussions as it positions HyBryte™ for potential commercialization.

To view the video, visit https://ibn.fm/zT9L1

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (“SGX301” or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.

For more information, visit the company’s website at https://www.soligenix.com

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Massimo Group (NASDAQ: MAMO), a manufacturer of powersports vehicles, is reinforcing its market position through strategic retail partnerships and a commitment to quality and innovation. By participating in key industry events like the Rural King Vendor Summit, the Tractor Supply Company and PetSense Annual Supplier Meeting and the Partner Trade Show, Massimo deepens ties with major retailers, gaining insights into customer needs and market trends. CEO David Shan emphasizes the company’s dedication to serving consumers who value reliable, high-performance products. Alongside expanding its reach through retail collaborations and a new online sales platform, Massimo enhanced operational efficiency by relocating its MVR Golf Cart production to its Texas facility. These efforts support the company’s proactive approach to market expansion and strategic growth.

To view the full article, visit https://ibn.fm/AsJen

About Massimo Group

Massimo Group is a manufacturer and distributor of powersports vehicles and pontoon boats. Founded in 2009, Massimo Motor believes it offers some of the most value packed UTVs, off-road, and on-road vehicles in the industry. The company’s product lines include a wide selection of farm and ranch tested utility UTVs, recreational ATVs, and Americana style mini-bikes. Massimo Marine manufactures and sells pontoon and tritoon boats with a dedication to innovative design, quality craftsmanship, and great customer service. Massimo Group is also developing electric versions of UTVs, golf-carts and pontoon boats. The company’s 376,000 square foot factory is in the heart of the Dallas / Fort Worth area of Texas in the city of Garland. For more information, visit massimomotor.com and massimomarine.com.

NOTE TO INVESTORS: The latest news and updates relating to MAMO are available in the company’s newsroom at https://ibn.fm/MAMO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Thumzup (NASDAQ: TZUP) is shaking up the multibillion-dollar marketing industry with the launch of its patent-pending Lifestyle AI Agent Marketplace. The company’s new AI application, Gibberlink Advertising(TM)—GibberAds(TM)—empowers users with AI agents with expertise in areas like fashion and dining, enabling curated experiences, ranging from a first date to a personal spa getaway, based on preferences and budget. According to the company, the platform is “designed to create demand for unique real-time offers made to Thumzup users by participating advertisers.” “The GibberAds service simultaneously facilitates business competitiveness through responsiveness to consumer interests, empowering social media influencers to wield a cutting-edge tool to appeal to their followers,” reads a recent article.

“Our Lifestyle AI Agent Marketplace is poised to redefine how people plan experiences and how businesses engage with them,” Thumzup CEO and Board Chairman Robert Steele was quoted as saying. “This is a multibillion-dollar opportunity and we look forward to continuing to innovate within the space.”

To view the full article, visit https://ibn.fm/ew1gp

About Thumzup Media Corp.

Thumzup Media Corporation is democratizing the multi-billion dollar social media branding and marketing industry. Its flagship product, the Thumzup platform, utilizes a robust programmatic advertiser dashboard coupled with a consumer-facing App to enable individuals to get paid cash for posting about participating advertisers on major social media outlets through the Thumzup App. The easy-to-use dashboard allows advertisers to programmatically customize their campaigns. Cash payments are made to App users/creators through PayPal and other digital payment systems.

Thumzup was featured on CBS Los Angeles and in KTLA.

NOTE TO INVESTORS: The latest news and updates relating to TZUP are available in the company’s newsroom at https://ibn.fm/TZUP

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Austin, Texas
www.TechMediaWire.com
512.354.7000 Office
[email protected]

TechMediaWire is powered by IBN

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”) announced the completion of physical assembly for its Advantage2^TM annealing quantum system at Davidson Technologies’ headquarters in Huntsville, Alabama. The system, the first of its kind hosted on-premises in the state, is entering final calibration and testing ahead of operational deployment. Developed in partnership with Davidson, the companies believe that the installation marks a pivotal step in advancing secure quantum computing capabilities for U.S. Department of Defense applications.

A private ribbon-cutting ceremony was held on April 23 to commemorate the milestone. The system is intended to support mission-critical quantum optimization efforts in areas such as space asset management and autonomous system coordination. 

To view the full press release, visit https://ibn.fm/C7nVQ 

About D-Wave Quantum Inc. 

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage^TMquantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2 systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com. 

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Disseminated on behalf of SolarBank Corporation

• Despite policy uncertainty, demand for scalable solar and storage solutions in North America remains strong, especially in commercial and community sectors, the Zacks report says.
• The company has a development pipeline exceeding 1 GW and is aiming to triple its owned capacity in the next two years.
• SolarBank is expanding from solar EPC services into independent power production (“IPP”) and battery energy storage systems (“BESS”).

Zacks Small-Cap Research has launched coverage of SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S. (https://ibn.fm/lYkSZ). The Zacks report highlights SolarBank’s growing role as an integrated energy firm with a strategy focused on building out its independent power production (“IPP”) capabilities and battery energy storage systems (“BESS”) to meet rising electricity demand in North America.

SolarBank is transitioning from an engineering, procurement, and construction (“EPC”) provider to owning and operating more of its own solar and storage assets. This shift is expected to improve revenue consistency and margins over time. The company is currently managing a project pipeline that exceeds…

Read More>>

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

HeartBeam (NASDAQ: BEAT), a medical technology firm innovating in personalized cardiac care, has announced a strategic collaboration with AccurKardia, a leader in ECG-based diagnostics. The partnership will integrate AccurKardia’s FDA-cleared ECG analysis software, AccurECG™, into HeartBeam’s compact, cable-free 3D ECG device. Designed to deliver 12-lead ECGs remotely, the device will be enhanced by automated arrhythmia assessments, aiming to accelerate diagnosis and improve access to cardiac care. The collaboration is expected to streamline HeartBeam’s product development while expanding the reach of remote cardiac monitoring solutions.

To view the full press release, visit https://ibn.fm/uRh5i

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com .

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

• Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs, just announced the successful completion of its review by the Italian Football Federation (“FIGC”)
• The FIGC’s regulatory process confirmed that Brera satisfied the standards of financial soundness and reputational integrity required by the regulations
• It marks a significant step forward in its mission to complete the acquisition of a majority stake in S.S. Juve Stabia S.r.l, dubbed “The Second Team of Naples”

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s professional sports clubs through a multi-club ownership (“MCO”) approach, just announced the successful completion of its review by the Italian Football Federation (“FIGC”) for the acquisition of a majority stake in S.S. Juve Stabia S.r.l. This was a requirement in Brera’s multi-phased quest to acquire a majority stake in “The Second Team of Naples,” a process that began in December 2024 (https://ibn.fm/Lqmeg).

“We are delighted to receive formal approval from the FIGC for our acquisition of a stake in Juve Stabia,” noted Daniel McClory, Brera Holdings’ Executive Chairman. “This marks a significant step forward in our mission to complete the acquisition of a majority stake in Juve Stabia and develop a…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

Newton Golf Company (NASDAQ: NWTG), a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design, was featured in the GotStocks Podcast as part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Dr. Greg Campbell, NWTG’s CEO, joined the program to discuss Newton Golf’s mission, vision and recent milestones.

“Newton Golf Company is a golf equipment company, but I like to think of it as a technology company. At our core, we have truly technically differentiated products. In fact, that’s why we rebranded to Newton Golf Company—after Sir Isaac Newton, who is known as the father of physics,” he said. “In all our products, it’s physics first, not gimmicks. That’s what truly differentiates us from the rest of the industry.”

To view the full press release, visit https://ibn.fm/wyP5B

About Newton Golf Company Inc.

Newton Golf harnesses the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, the company’s rebranding reflects its commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of its design process, Newton Golf creates precision-engineered golf clubs that deliver unmatched stability, control, and performance. The company’s mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics.

For more information, visit the company’s website at www.NewtonGolfIR.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

• Nutriband secures new U.S. trademark and international patents for AVERSA(TM) platform
• AVERSA(TM) Fentanyl targets $80M–$200M U.S. sales opportunity as first abuse-deterrent opioid patch
• Strategic sports partnership with Charlotte FC boosts brand visibility and community presence

Strengthening IP for Long-Term Market Protection

Nutriband (NASDAQ: NTRB) continues to solidify its leadership in the development of abuse-deterrent transdermal pharmaceuticals. In February, the company received a trademark registration from the U.S. Patent and Trademark Office (“USPTO”) for “Nutriband(TM),” covering pharmaceutical and product R&D. This comes in addition to a newly granted patent in Macao for its proprietary AVERSA(TM) transdermal system, bringing the total number of countries granting protection to 46.

These intellectual property milestones reflect the growing importance of Nutriband’s AVERSA(TM) platform, which is designed to reduce abuse, diversion, and accidental exposure of potent drugs like fentanyl. With patents now spanning the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• Ford Otosan has deployed into production a hybrid-quantum application to optimize production sequencing for its highly customizable Ford Transit vehicles.
• The application, developed with D-Wave’s annealing quantum computing technology, reduces scheduling time by over 80%.
• Ford Otosan is using the quantum optimization solution to help manage vehicle variability, labor constraints, and shop-floor dependencies more effectively than by using just classical computing approaches.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, announced that its technology is being deployed in a live manufacturing environment at Ford Otosan’s production facility in Turkey. The hybrid-quantum application is aimed at optimizing the manufacturing sequencing of Ford Transit vehicles, which are produced in thousands of different configurations to meet customer specifications (https://ibn.fm/UgxSP).

Ford Otosan, a joint venture between Ford Motor Company and Koç Holding, is the largest commercial vehicle production hub in Ford’s European network. It manufactures over 700,000 vehicles annually, including the highly customizable Ford Transit line. The complexity of this model line—featuring…

Read More>>

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage(TM) quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2(TM) systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) announced plans to develop a 4.584 MW DC ground-mount solar project in upstate New York, known as the Forest Hill Rd project. The site lease is secured, and an interconnection study is in progress. Once completed, the project will operate as a community solar initiative and is eligible for New York’s VDER rate mechanism and NYSERDA NY-Sun incentives. SolarBank emphasized its supply chain resilience, noting that its operations are unaffected by the U.S. tariff hikes on Southeast Asian solar imports. The company continues sourcing panels from cost-competitive regions such as the Middle East and North America. 

To view the full press release, visit https://ibn.fm/FXILJ 

About SolarBank Corporation 

SolarBank Corporation is an independent renewable and clean energy project developer and owner focusing on distributed and community solar projects in Canada and the USA . The Company develops solar, Battery Energy Storage System (BESS) and EV Charging projects that sell electricity to utilities, commercial, industrial, municipal and residential off-takers. The Company maximizes returns via a diverse portfolio of projects across multiple leading North America markets including projects with utilities, host off-takers, community solar, and virtual net metering projects. The Company has a potential development pipeline of over one gigawatt and has developed renewable and clean energy projects with a combined capacity of over 100 megawatts built.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Brera Holdings (NASDAQ: BREA) announced that its Serie B portfolio club, S.S. Juve Stabia, has rescheduled its home match against Sampdoria to May 13, 2025, at 20:30 CET. The adjustment follows a league-wide postponement of Round 34 fixtures in observance of the national mourning period declared after the passing of Pope Francis. All previously purchased tickets remain valid. The club will also observe a minute of silence in line with Italian football’s tribute efforts.

To view the full press release, visit https://ibn.fm/PRLBX

About Brera Holdings PLC

Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.

For more information, visit the company’s website at www.BreraHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at http://ibn.fm/BREA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

• An increase in deaths from COVID-19 underscores the persistent danger of the virus and the urgent need for effective protective measures and treatments.
• Soligenix is addressing this need through the development of CiVax, its proprietary, heat-stable COVID-19 subunit vaccine candidate.
• Recent preclinical studies have demonstrated that CiVax can induce rapid and broad protection against multiple COVID-19 variants.

Despite the passage of time since the pandemic, COVID-19 continues to pose a significant global health threat. Recent data from the World Health Organization (“WHO”) indicates that during the 28-day period from Jan. 6 to Feb. 2, 2025, more than 147,000 new COVID-19 cases were reported globally, representing a 16% decrease compared to the previous period (https://ibn.fm/viChU). However, during the same timeframe, approximately 4,500 new deaths were reported, marking a 28% increase. This underscores the persistent danger of the virus and the urgent need for effective protective measures and treatments.

In the United States, the Centers for Disease Control and Prevention (“CDC”) reported that as of April 11, 2025, the levels of acute respiratory illnesses, including COVID-19, remain low (https://ibn.fm/tTcxB). Nevertheless, the virus continues to circulate, and the potential for new…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• Social media commerce is expected to grow to $821 billion in 2025_[1], demonstrating its importance as a medium for advertiser success
• Advertising tech platform developer Thumzup Media has created a proprietary product that bridges gaps between advertisers and social media influencers to target the opportunity social media provides
• Thumzup has recently expanded from its Los Angeles base to the South Florida market, and uplisted to the Nasdaq exchange as part of its continued growth
• The company recently registered its 800th advertising client with plans to pass the 1,000-client threshold within the next couple of months, building on its growth CAGR of 243% during the past year

Social media branding and marketing innovator Thumzup (NASDAQ: TZUP) is following in the footsteps of community network companies like Uber and Airbnb, forging a path to success in its own industry with a user-friendly platform to help America’s small business community efficiently reach consumers.

Thumzup’s mission is to help companies sell their products and services by connecting their advertising campaigns to social media influencers who can appeal directly to their own followers to generate a potential customer pool. “As a leader in authentic and creator-driven social media advertising, our…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to TZUP are available in the company’s newsroom at https://ibn.fm/TZUP

[1] https://www.oberlo.com/statistics/social-commerce-market-size

About TechMediaWire

TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TechMediaWire.com

Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer

TechMediaWire
Los Angeles, CA
www.TechMediaWire.com
310.299.1717 Office
[email protected]

TechMediaWire is powered by IBN

Mullen Automotive (NASDAQ: MULN), an electric vehicle manufacturer, announced a 20-unit order of its all-electric Class 3 Mullen THREE trucks from Houston-based logistics company Cashflow on Wheels. Valued at approximately $1.4 million, the order will be fulfilled by Mullen dealer Pritchard Automotive. Cashflow on Wheels, which services clients such as FedEx and Amazon, cited cost savings of over $500 per route per week from EV testing as the catalyst for its transition to electric vehicles.

To view the full press release, visit https://ibn.fm/2OOdO

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

• At its Qubits 2025 user conference, D-Wave introduced new hybrid solver capabilities supporting continuous variables and aims to broaden its commercial use cases and increase adoption of its quantum optimization technology.
• The company is seeing increased interest from customers, independent software vendors, system integrators, and resellers and has revealed new quantum optimization use cases including portfolio optimization, offer allocation, and maintenance repair operations.
• Companies such as NTT DOCOMO and Ford Otosan are already deploying D-Wave’s quantum optimization technology in production environments.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has announced an expanded suite of tools and use cases designed to accelerate adoption of its commercial quantum optimization technology. Presented at the company’s Qubits 2025 user conference, the new solutions reflect growing interest in quantum solutions for real-world business problems from customers, independent software vendors (“ISVs”), system integrators (“SIs”), and resellers (https://ibn.fm/Q7ODq).

D-Wave announced new functionality within its hybrid quantum nonlinear (“NL”) solver, which now supports continuous variables with linear interactions. This added capability enables the solver to address a wider range of computational problems, including dynamic resource distribution and…

Read More>>

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage(TM) quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2(TM) systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Mullen Automotive (NASDAQ: MULN) announced that its subsidiary, Bollinger Motors, has delivered the first 2025 Bollinger B4 electric truck to EnviroCharge for conversion into a mobile Level 3 charging unit. The upfitted truck will debut at the ACT Expo 2025 in Anaheim before being deployed in California to address growing EV infrastructure demand. EnviroCharge selected the Class 4 B4 platform for its performance and reliability, supporting its mission to expand on-the-go charging. Bollinger Motors’ trucks also qualify for up to $120,000 in incentives across multiple federal and state programs. 

To view the full press release, visit https://ibn.fm/upgV0 

About Mullen Automotive Inc. 

Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com. 

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN 

About GreenCarStocks

GreenCarStocks (“GCS”) is a specialized communications platform with a focus on electric vehicles (“EVs”) and the green energy sector. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled recognition and brand awareness. GCS is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from GreenCarStocks, text “Green” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the GreenCarStocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

GreenCarStocks
Austin, Texas
www.GreenCarStocks.com
512.354.7000 Office
[email protected]

GreenCarStocks is powered by IBN

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., is reinforcing its role in powering the future through solar, battery storage, and EV charging projects. In recent interviews on InvestorBrandNetwork’s Bell2Bell and Electrek’s Quick Charge podcasts, CEO Richard Lu highlighted the company’s vertically integrated model, strategic partnerships—including a $50 million contract with Qcells and a new collaboration with Viridi—and its robust project pipeline exceeding 1 gigawatt of capacity. SolarBank is currently advancing major battery energy storage systems (“BESS”) and solar initiatives in Ontario and New York, supported by long-term contracts and millions in owned assets. With a focus on reliable, clean power delivery, Lu emphasized SolarBank’s commitment to sustainable growth, community impact, and advancing energy infrastructure.

To view the full article, visit https://ibn.fm/6EvF8

About SolarBank Corporation

SolarBank Corporation is an independent renewable and clean energy project developer and owner focusing on distributed and community solar projects in Canada and the USA. The company develops solar, battery energy storage system (“BESS”) and EV charging projects that sell electricity to utilities, commercial, industrial, municipal and residential off-takers. The company maximizes returns via a diverse portfolio of projects across multiple leading North America markets including projects with utilities, host off-takers, community solar, and virtual net metering projects. The company has a potential development pipeline of over one gigawatt and has developed renewable and clean energy projects with a combined capacity of over 100 megawatts built.

For more information, visit the company’s website at SolarBankCorp.com. This report contains forward-looking information. Please refer to https://ibn.fm/G76GJ for additional details.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan has been named a finalist in the Established category of the 2025 EY Entrepreneur of the Year Awards. Sheridan is one of 27 Irish entrepreneurs recognized for their leadership and impact, with finalists selected from across 24 companies generating more than €1 billion in annual revenue. 

Sheridan is being recognized for his role in transforming Nutriband from an early-stage startup into a U.S.-listed life sciences company focused on transdermal drug delivery and abuse-deterrent technologies. The company’s lead product, AVERSA™, is designed to prevent the misuse and abuse of opioid patches—addressing a critical gap in pain management. 

Finalists in the EY program will participate in a CEO retreat in Japan and compete for the overall Entrepreneur of the Year title, to be awarded at a gala event in November. 

To view the full article, visit https://ibn.fm/FNBFI 

About Nutriband Inc. 

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information about the company, visit www.Nutriband.com. 

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

Brera Holdings (NASDAQ: BREA) announced that its Serie B club, S.S. Juve Stabia, achieved its highest home attendance of the season with 7,000 fans at the April 5 derby against Salernitana—just shy of a sellout at Stadio Romeo Menti. The turnout marks a key step in the club’s commercial strategy to boost matchday revenue and long-term fan engagement. Juve Stabia ranks 5th in Serie B and has seen its squad value surge 36.9% to €16.13 million, as Brera advances its multi-club ownership model through both on-field success and off-field monetization.

To view the full press release, visit https://ibn.fm/ICngt

About Brera Holdings PLC

Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to earn tournament prizes, gain sponsorships, provide other professional football and sports-related consulting services, and achieve capital appreciation of these clubs.

For more information, visit the company’s website at www.BreraHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at http://ibn.fm/BREA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

• Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients.
• AVERSA technology can be incorporated into any transdermal patch.
• The company has a broad and expanding intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China.
• Nutriband closed an $8.4 million financing round in April 2024 to support commercial development of AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch.
• In February 2025, the company formalized a long-term exclusive partnership with Kindeva Drug Delivery to support AVERSA Fentanyl’s pathway to market.

Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Newton Golf Company (NASDAQ: NWTG), a technology-forward golf brand, has appointed Andy Harris and Jeff Opheim as new Tour representatives for the PGA TOUR, PGA TOUR Champions, and Korn Ferry Tour. Founder and CTO Aki Yorihiro will also serve as a Tour representative for the LPGA and PGA TOUR Champions, reinforcing Newton Golf’s footprint across top-tier golf circuits. With a growing ambassador portfolio and over 30 professionals using its Newton Motion shafts and Gravity putters, the company is focused on leveraging swing data and performance feedback to drive innovation and brand growth.

To view the full press release, visit https://ibn.fm/HPgUb

About Newton Golf

At Newton Golf, we harness the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, our rebranding reflects our commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of our design process, we create precision-engineered golf clubs that deliver unmatched stability, control, and performance. Our mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN